Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat

Experimental Neurology

Volumn 150, Issue 2, 1998, Pages 223-234

  Duty, Susan ^b   Henry, Brian ^a   Crossman, Alan R ^a   Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dynorphin; Enkephalin; In situ hybridization; L DOPA induced dyskinesia; Parkinson's disease; Preproenkephalin A; Preproenkephalin B

Indexed keywords

APOMORPHINE; DOPAMINE; DYNORPHIN; ENKEPHALIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; OPIATE PEPTIDE; OXIDOPAMINE; PREPROENKEPHALIN; PRODYNORPHIN; PROTEIN PRECURSOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DYSKINESIA; IN SITU HYBRIDIZATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PUTAMEN; RAT;

EID: 17344390118     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6771     Document Type: Article

References (68)

1. Alexander G. E., Crutcher M. D., DeLong M. R. Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog. Brain Res. 85:1990;119-146.
2. Altschul S. F., Gish W., Miller W., Myers E. W., Lipman D. J. Basic logical alignment search tool. J. Mol. Biol. 215:1990;403-410.
3. Angulo J., Davis L., Burkhart B., Christoph G. Reduction of striatal neurotransmission elevates striatal proenkephalin mRNA. Eur. J. Pharmacol. 130:1986;341-243.
4. Angulo J. A. Involvement of dopamine D1 and D2 receptors in the regulation of preproenkephalin mRNA abundance in the striatum and accumbens of the rat brain. J. Neurochem. 58:1992;1104-1109.
5. Arcari P, Martinelli R., Salvatore F. The complete sequence of a full length cDNA for human liver glyeraldehyde-3-phosphate dehydrogenase: Evidence for multiple mRNA species. Nucleic Acids Res. 12:1984;9179-9189.
6. 3. Brain Res. 379:1986;294-299.
7. Berendse H. W., Galis-de Graaf Y., Groenewegen H. J. Topographical organisation and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J. Comp. Neurol. 316:1992;314-347.
8. Bevan P. Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity. Neurosci. Letts. 35:1983;185-189.
9. Buonamici M., Caccia C., Carpentieri M., Pegrassi L., Rossi A. C., DiChiara G. D-1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. Eur. J. Pharmacol. 126:1986;347-348.
10. Campbell K., Björklund A. Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum. Eur. J. Neurosci. 6:1994;1371-1383.
11. Carey R. J. Chronic L-DOPA treatment in the unilateral 6-OHDA rat: Evidence for behavioural sensitization and biochemical tolerance. Brain Res. 568:1991a;205-214.
12. Carey R. J. Naloxone reverses L-DOPA induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci. 48:1991b;1303-1308.
13. Carroll C. B., Holloway V., Brotchie J. M., Mitchell I. J. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: Functional implications for the treatment of parkinsonian symptoms. Psychopharmacology. 119:1995;55-65.
14. Civelli O., Douglass J., Goldstein A., Herbert E. Sequence and expression of the rat prodynorphin gene. Proc. Natl. Acad. Sci. USA. 82:1985;4291-4295.
15. Crossman A. R. An hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement Disorders. 5:1990;100-108.
16. DeLong M. R., Georgopoulos A. P. Motor functions of the basal ganglia. Handbook of Physiology, Sect. 1. The Nervous System, Vol. 2, Motor Control, Part 2. 1981;Am. Phys. Soc. Bethesda. p. 1017-1061.
17. Del Fiacco M., Paxinos G., Levanti M. C. Neostriatal enkephalin immunoreactive neurons project to the globus pallidus. Brain Res. 231:1982;1-17.
18. Duty S., Henry B., Crossman A. R., Brotchie J. M. Speculations on the neural mechanisms underlying the dyskinetic side-effects of dopamine replacement therapy in parkinsonism. Brain Res. Assoc. Abstr. 12:1995;41.2.
19. Duty S., Brotchie J. M. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp. Neurol. 144:1997;423-432.
20. Engber T. M., Susel Z., Juncos J-L., Chase T. N. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur. J. Pharmacol. 168:1989;291-298.
21. Engber T. M., Susel Z., Kuo S., Gerfen C. R., Chase T. N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res. 552:1991;113-118.
22. Gagnon C., Bédard P. J., Rioux L., Gaudin D., Martinoli M. G., Pelletier G., Di Paolo T. Regional changes of striatal dopamine receptors following denervation by 6-hydroxydopamine and fetal mesencephalic grafts in the rat. Brain Res. 558:1991;251-263.
23. Gerfen C. G., Young W. S. III. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: Anin situ. Brain Res. 460:1988;161-167.
24. Gerfen C. R., McGinty J. F., Young W. S. III. Dopamine differentially regulates dynorphin, substance P and enkephalin expression in striatal neurons: In situ hybridisation histochemical analysis. J. Neurosci. 11:1991;1016-1031.
25. Gomez-Mancilla B., Bédard P. J. Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16:1993;418-427.
26. Goldman P. S., Nauta W. J. H. An intricately patterned prefronto-caudate projection in the rhesus monkey. J. Comp. Neurol. 171:1977;369-386.
27. 21. Brain Res. 514:1990;93-102.
28. Graybiel A. M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-254.
29. Greenamyre J. T. Glutamate-dopamine interactions in the basal ganglia: Relationship to Parkinson's disease. J. Neurotransm. 91:1993;255-269.
30. Haber S. N., Lynd E., Klein C., Groenewegen H. J. Topographical organisation of the ventral striatal efferent projections in the rhesus monkey: an anterograde tracing study. J. Comp. Neurol. 293:1990;282-288.
31. Henry B., Brotchie J. M. Potential of Opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging. 9:1996;1-10.
32. Herrero M-T., Augood S. J., Hirsch E. C., Javoy-Agid F., Luquin M. R., Agid Y., Obeso J. A., Emson P. C. Effects of L-Dopa on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience. 86:1995;1189-1198.
33. 3. Neuroscience. 46:1992;687-700.
34. Hossain M. H., Weiner N. Dopaminergic functional supersensitivity: effects of chronic L-Dopa and carbidopa treatment in an animal model of Parkinson's disease. J. Pharmacol. Exp. Ther. 267:1993;1105-1111.
35. Howells R. D., Kilpatrick D. L., Bhatt R., Monahan J. J., Poonian M., Udenfriend S. Molecular cloning and sequence determination of rat preproenkephalin cDNA: Sensitive probes for studying transcriptional changes in rat tissues. Proc. Natl. Acad. Sci. USA. 81:1984;7651-7655.
36. Jiang H. K., McGinty J. F., Hong J. S. Differential modulation of strionigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Res. 507:1990;57-64.
37. Jolkkonen J., Jenner P., Marsden C. D. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Brain Res. Mol. Brain Res. 32:1995;297-307.
38. Juncos J. L., Engber T. M., Raisman R., Susel Z., Thibaut F., Ploska A., Agid Y., Chase T. N. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann. Neurol. 25:1989;473-478.
39. Kelley A. E., Domesick V. B. The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde and retrograde horseradish peroxidase study. Neuroscience. 7:1982;2321-2325.
40. 2. Neuroscience. 53:1993;665-672.
41. Kunzle H. Bilateral projections from the precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study in Macaca fascicularis. Brain Res. 88:1975;195-209.
42. Kunzle H. Projections from the primary somatosensory cortex to the basal ganglia and thalamus in the monkey. Exp. Brain Res. 30:1977;481-492.
43. Li S. J., Jiang H. K., Stachowiak M. S., Hudson P. M., Owyang V., Nanry K., Tilson H. A., Hong J. S. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. Mol. Brain Res. 8:1990;219-225.
44. Maneuf Y. P., Mitchell I. J., Crossman A. R., Brotchie J. M. On the role of enkephalin in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol. 125:1994;65-71.
45. Marsden C. D., Parkes J. D. Success and problems of long term therapy in Parkinson's disease. Lancet. I:1977;345-349.
46. Marshall J. F., Navarrete R., Joyce J. N. Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis. Brain Res. 493:1989;247-257.
47. Martin J. P. Hemichorea resulting from a local lesion of the brain (syndrome of body of Luys). Brain. 50:1927;637-651.
48. Mishra R. M., Marshall A. M., Varmuza S. L. Supersensitivity in rat caudate nucleus: effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes. Brain Res. 200:1980;47-57.
49. Mitchell I. J., Joyce S., Sambrook M. A., Crossman A. R. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain: implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain. 115:1992;809-824.
50. 12. Neuroscience. 25:1988;525-532.
51. Normand E., Popovici T., Onteniente B., Fellmann D., Piatier-Tonneau D., Auffray C., Bloch B. Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons. Brain Res. 439:1988;39-46.
52. Pan H. S., Penney J. B., Young A. B. GABA and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. J. Neurosci. 45:1985;1396-1404.
53. Papa S. M., Engber T. M., Kask A. M., Chase T. N. Motor fluctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
54. Parent A., Hazrati L-N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev. 20:1995;91-127.
55. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press.
56. Rosen H., Douglass J., Herbert E. Isolation and characterisation of the rat proenkephalin gene. J. Biol. Chem. 259:1984;14309-14313.
57. 5. J. Pharmacol. Exp. Ther. 262:1992;823-833.
58. Thomas K. L., Rose S., Jenner P., Marsden C. D. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation. Biochem. Pharmacol. 44:1992;73-82.
59. Trabucchi M., Bassi S., Frattola L. Effect of naloxone on the 'On-Off' syndrome in patients receiving long-term levodopa therapy. Arch. Neurol. 39:1982;120-121.
60. Uhl G. R., Navia B., Douglas J. Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: High levels of preproenkephalin expression depend on cortical afferents. J. Neurosci. 8:1988;4755-4764.
61. Ungerstedt U., Avema A. E., Ljundberg T., Runge C. Animal models of parkinsonism. Adv. Neurol. 3:1973;257-271.
62. Vincent S. R., Hökfelt T., Christensson I., Terenius L. Immunohistochemical evidence for a dynorphin immunoreactive strionigral pathway. Eur. J. Pharmacol. 85:1982;251-252.
63. Voorn P., Poest G., Groenwegen H. J. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412:1987;391-396.
64. Voorn P., Docter G. J., Jongen-Rêlo A. L., Jonker A. J. Rostrocaudal sub-regional differences in the response of enkephalin, dynorphin and substance P synthesis in rat nucleus accumbens to dopamine depletion. Eur. J. Neurosci. 6:1994;486-496.
65. Whittier J. R., Mettler F. A. Studies on the subthalamus of rhesus monkey. II. Hyperkinesia and other physiological effects of subthalamic lesions, with special reference to the subthalamic nucleus of Luys. J. Comp. Neurol. 90:1949;319-372.
66. Xie C.-W., Lee P. H. K., Douglass J., Crain B., Hong J. S. Deep prepyriform cortex kindling differentially alters the levels of prodynorphin mRNA in rat hippocampus and striatum. Brain Res. 495:1989;156-160.
67. Young W. S. III, Bonner T. I., Brann M. R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
68. Zahm D. S., Brog J. S. On the significance of subterritories in the 'accumbens' part of the ventral striatum. Neuroscience. 50:1992;751-767.